Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ch128.1 Fc mutant
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ch128.1 Fc mutant is a modified version of the mouse/human chimeric IgG3 antibody ch128.1, which targets the human transferrin receptor 1 (TfR1), also known as CD71. This specific mutant is engineered with mutations in the Fc region to impair its binding to Fc gamma receptors (FcγRs) and the complement component C1q, thereby abrogating its ability to trigger antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). In preclinical research, particularly in xenograft models of multiple myeloma, this mutant serves as a critical tool to demonstrate that the in vivo efficacy of the parent ch128.1 antibody is dependent on host effector functions rather than solely on direct cytotoxicity via iron deprivation or receptor degradation.
- Other names
- anti-TfR1 ch128.1 Fc mutantanti-TfR-1 ch128.1 Fc mutantanti-TfR 1 ch128.1 Fc mutant
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on ch128.1 Fc mutant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ch128.1 Fc mutant.